Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image-Guided Intensity-Modulated Radiotherapy for Localized High-Risk Prostate Adenocarcinoma

Prostate Adenocarcinoma ◽

Image Guided ◽

Weekly Docetaxel ◽

Intensity Modulated ◽

Androgen Blockade

Final Results of a Phase I Trial of Total Androgen Blockade, Weekly Docetaxel, and Image-guided Intensity Modulated Radiotherapy for Localized High-risk Prostate Cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2011.06.635 ◽

2011 ◽

Vol 81 (2) ◽

pp. S395

Author(s):

D.T. Marshall ◽

A. Golshayan ◽

A. Kraft ◽

U. Chaudhary

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Phase I Trial ◽

Image Guided ◽

Weekly Docetaxel ◽

Intensity Modulated ◽

Risk Prostate Cancer ◽

Androgen Blockade

Phase I Trial of Androgen Deprivation, Weekly Docetaxel and Concurrent Intensity Modulated Radiation Therapy (IMRT) in the Treatment of High-risk Prostate Adenocarcinoma

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2009.07.754 ◽

2009 ◽

Vol 75 (3) ◽

pp. S329

Author(s):

J.A. Fortney ◽

A.S. Kraft ◽

A. Golshayan ◽

D.T. Marshall

Keyword(s):

Radiation Therapy ◽

High Risk ◽

Phase I ◽

Phase I Trial ◽

Intensity Modulated Radiation Therapy ◽

Prostate Adenocarcinoma ◽

Androgen Deprivation ◽

Weekly Docetaxel ◽

Intensity Modulated

A phase I study of adjuvant intensity-modulated radiotherapy with concurrent paclitaxel and cisplatin for cervical cancer patients with high risk factors

Medical Oncology ◽

10.1007/s12032-015-0689-5 ◽

2015 ◽

Vol 32 (11) ◽

Cited By ~ 3

Author(s):

Pei Shu ◽

Yali Shen ◽

Yaqin Zhao ◽

Feng Xu ◽

Meng Qiu ◽

...

Keyword(s):

Risk Factors ◽

Cervical Cancer ◽

High Risk ◽

Phase I ◽

Cancer Patients ◽

Phase I Study ◽

Intensity Modulated ◽

High Risk Factors

Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC)

Annals of Oncology ◽

10.1093/annonc/mdx374.014 ◽

2017 ◽

Vol 28 ◽

pp. v379 ◽

Cited By ~ 1

Author(s):

R.L. Ferris ◽

D.A. Clump ◽

J. Ohr ◽

W. Gooding ◽

S. Kim ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Phase I ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase I Trial ◽

Locally Advanced ◽

Advanced Head ◽

Intensity Modulated

Image-guided, whole-pelvic, intensity-modulated radiotherapy for biochemical recurrence following radical prostatectomy in high-risk prostate cancer patients

PLoS ONE ◽

10.1371/journal.pone.0190479 ◽

2018 ◽

Vol 13 (1) ◽

pp. e0190479 ◽

Cited By ~ 5

Author(s):

Sang Jun Byun ◽

Young Seok Kim ◽

Hanjong Ahn ◽

Choung-Soo Kim

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Radical Prostatectomy ◽

Cancer Patients ◽

Biochemical Recurrence ◽

Image Guided ◽

Intensity Modulated ◽

Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2019.11.418 ◽

2020 ◽

Vol 106 (5) ◽

pp. 939-947

Author(s):

Jianqing Lin ◽

Robert B. Den ◽

Jacob Greenspan ◽

Timothy N. Showalter ◽

Jean H. Hoffman-Censits ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Phase I ◽

Androgen Deprivation Therapy ◽

Phase I Trial ◽

Androgen Deprivation ◽

Intensity Modulated ◽

Clinical Application of High-Dose, Image-Guided Intensity-Modulated Radiotherapy in High-Risk Prostate Cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2009.05.006 ◽

2010 ◽

Vol 77 (2) ◽

pp. 477-483 ◽

Cited By ~ 22

Author(s):

Andrew Bayley ◽

Tara Rosewall ◽

Tim Craig ◽

Rob Bristow ◽

Peter Chung ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Clinical Application ◽

High Dose ◽

Image Guided ◽

Intensity Modulated ◽

A Phase II Study Evaluating Bone Marrow-Sparing, Image-guided Pelvic Intensity-Modulated Radiotherapy (IMRT) With Cesium-131 Brachytherapy Boost, Adjuvant Chemotherapy, and Long-Term Hormonal Ablation in Patients With High Risk, Nonmetastatic Prostate Cancer

American Journal of Clinical Oncology ◽

10.1097/coc.0000000000000520 ◽

2019 ◽

Vol 42 (3) ◽

pp. 285-291 ◽

Cited By ~ 1

Author(s):

Stephanie R. Rice ◽

Gloribel Olexa ◽

Arif Hussain ◽

Heather Mannuel ◽

Michael J. Naslund ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Marrow ◽

High Risk ◽

Phase Ii Study ◽

Image Guided ◽

Intensity Modulated ◽

Brachytherapy Boost ◽

Bone Marrow Sparing

Phase I trial of weekly cabazitaxel with concurrent intensity modulated radiation therapy (IMRT) and androgen deprivation therapy (ADT) for the treatment of high-risk prostate cancer (PCa).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e16009 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e16009-e16009

Author(s):

Jianqing Lin ◽

Robert Benjamin Den ◽

Timothy N Showalter ◽

Jean H. Hoffman-Censits ◽

Monica McGuire ◽

...

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

High Risk ◽

Phase I ◽

Androgen Deprivation Therapy ◽

Phase I Trial ◽

Intensity Modulated Radiation Therapy ◽

Intensity Modulated ◽

Phase I Trial of Hypofractionated Intensity-Modulated Radiotherapy With Temozolomide Chemotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2010.07.021 ◽

2011 ◽

Vol 81 (4) ◽

pp. 1066-1074 ◽

Cited By ~ 36

Author(s):

Changhu Chen ◽

Denise Damek ◽

Laurie E. Gaspar ◽

Allen Waziri ◽

Kevin Lillehei ◽

...

Keyword(s):

Glioblastoma Multiforme ◽

Phase I ◽

Phase I Trial ◽

Newly Diagnosed ◽

Intensity Modulated ◽

Newly Diagnosed Glioblastoma ◽

Temozolomide Chemotherapy